The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

Some users of GLP-1 weight-loss drugs have been reporting strange changes in food preferences, such as a new dislike for ...

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Recently, the FDA announced the removal of certain compounded GLP1 ingredients from its drug shortage list. These ingredients are found in: The drug products were in shortage since 2020. The FDA had ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...

The maker of Wegovy is making the drug available to several telehealth companies and also plans to make it more affordable ...

Experts share why a diet rich in plant-based, nutrient-dense foods is key to staying healthy when using medications that curb ...

Shares of Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) are surging on Tuesday. Shares soared after pharma giant Novo Nordisk announced it will distribute its blockbuster GLP-1 weight loss ...

Just today, this drug became more widely available. Some product is now facing a recall following an apparent storage error.

The maker of Wegovy is making the GLP1 medication available to several telehealth companies.

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers have struck a truce after sparring over ...